You Position: Home > Paper
Clinical research on prediction marker of efficacy in advanced non-small cell lung cancer
( views:408, downloads:400 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 9
- DOI:
- 10.3760/cma.j.issn.1006-9801.2010.09.002
- Key Word:
- 癌,非小细胞肺;靶向治疗;生物学标志;Carcinoma,non-small-cell lung;Target therapy;Biological marker
Abstract： Individualized therapy is the current trend of treatment in advanced non-small cell lung cancer, the key of individualized therapy is to administrer different treatment options through different biological markers or clinical markers. Currently, biological markers include EGFR protein expression, EGFR mutations, EGFR gene copy, k-ras mutation, EML4-ALK gene fusion, C-MET gene. Clinical markers include rash, pathological types, etc. This article will give a review about those biomarkers.
- [1]Patel T,Lynch TJ,Dreisbach.Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.[J].2010,28(6).
- [2]Turke AB,Zejnullahu K,Wu Y.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.[J].2010,17(1).
- [3]Shaw AT,Mino Kenudson M,Yeap BY.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.[J].2009,27(26).
- [4]Eberhard DA,Johnson BE,Amler LC,etc.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.[J].2005,23(25).
- [5]Seymour L,Zhang T,Marrano P,etc.Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.[J].2008,26(26).
- [6]Gyurkovits K,Soldatenkova V,Ulsperger E,etc.Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.[J].2006,52(2).
- [7]Toschi L,Cappuzzo F.Clinical implications of MET gene copy number in lung cancer.[J].2010,6(2).
- [8]Asangani IA,Mills GB,Nelson LD,etc.Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.[J].2009,69(6).
- [9]Kurie JM,Cascone T,Nikolinakos PG,etc.Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.[J].2010,29(18).